Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$67.81 USD

67.81
4,294,477

-0.25 (-0.37%)

Updated Aug 15, 2025 04:00 PM ET

After-Market: $67.84 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (151 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Add Phibro (PAHC) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Phibro (PAHC), owing to its potential in Performance Products and consistent high demand for its nutritional specialty products.

Zacks Equity Research

Hologic (HOLX) to Buy Mobidiag, Boost Diagnostics Testing Arm

by Zacks Equity Research

Hologic's (HOLX) Mobidiag acquisition will generate long-term value by enabling the company to tap into the global acute care market.

Sriparna Ghosal headshot

3 Women Healthcare Stocks With Solid Growth Potential Amid COVID-19

by Sriparna Ghosal

Let's take a look at the three women healthcare MedTech stocks performing well lately.

Zacks Equity Research

Cardinal Health (CAH) Unveils Navista TS to Boost Patient Care

by Zacks Equity Research

Cardinal Health (CAH) Specialty Solutions' newly launched Navista TS will help community oncologists to improve patient care and become successful in value-based care while reducing costs.

Zacks Equity Research

Globus Medical (GMED) Hurt by Dull Global Growth, Low Margins

by Zacks Equity Research

Pricing continues to remain a major headwind for Globus Medical (GMED).

Zacks Equity Research

Omnicell's (OMCL) Automated Dispensing Service Adopted by Aultman

by Zacks Equity Research

Omnicell's (OMCL) Autonomous Pharmacy vision receives another boost with the latest service adoption by Aultman.

Trina Mukherjee headshot

3 GARP MedTech Stocks to Snap Up Despite Pandemic Woes

by Trina Mukherjee

Here we look at three stocks, OMI, HOLX and QGEN, that investors can add to their watchlist backed by robust long-term prospects.

Zacks Equity Research

3 Reasons Why Hologic (HOLX) Is a Great Growth Stock

by Zacks Equity Research

Hologic (HOLX) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Here's Why You Should Retain Integer Holdings (ITGR) Stock

by Zacks Equity Research

Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.

Zacks Equity Research

QIAGEN (QGEN) Launches QIAseq Kit, Enhances COVID-19 Portfolio

by Zacks Equity Research

QIAGEN's (QGEN) latest kit is likely to significantly reduce library turnaround times and plastics usage, thus allowing more accurate detection and quantification of molecular variants.

Zacks Equity Research

Allscripts' (MDRX) Solution Gets Selected by Revo Health

by Zacks Equity Research

Allscripts' (MDRX) Practice Management solution to improve financial and operational performance of all i-Health clinics of Revo Health.

Zacks Equity Research

Are Investors Undervaluing Hologic (HOLX) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

HOLX vs. SMLR: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

HOLX vs. SMLR: Which Stock Is the Better Value Option?

Zacks Equity Research

Illumina (ILMN) Preliminary Q1 Revenues Rebound, '21 View Up

by Zacks Equity Research

Illumina's (ILMN) revenue improvement in the first quarter is likely to have been boosted by on-going business recovery.

Zacks Equity Research

Here's Why You Should Hold on to Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Bruker (BRKR) on its slew of product launches and potential in the BSI Nano Group.

Zacks Equity Research

Here's Why You Should Retain Intuitive Surgical (ISRG) Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System. However, weakness at the Systems segment is a woe.

Zacks Equity Research

OPKO Health's (OPK) BioReference Extends Sports Partnerships

by Zacks Equity Research

OPKO Health's (OPK) BioReference expands its major league sports relationships with the announcement of COVID-19 testing agreement with MLB.

Zacks Equity Research

Zacks Industry Outlook Highlights: Natus Medical, IDEXX Laboratories, Hologic, Thermo Fisher Scientific and Abiomed

by Zacks Equity Research

Zacks Industry Outlook Highlights: Natus Medical, IDEXX Laboratories, Hologic, Thermo Fisher Scientific and Abiomed

Zacks Equity Research

Hologic (HOLX) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Hologic (HOLX) closed at $73.87, marking a -0.44% move from the previous day.

Zacks Equity Research

Late-Breaking Data Supports Boston Scientific's (BSX) TheraSphere

by Zacks Equity Research

Boston Scientific's (BSX) TheraSphere is expected to be used as a safe and effective treatment option for numerous HCC patients worldwide on the back of positive trial results.

Zacks Equity Research

Here's Why You Should Retain Henry Schein (HSIC) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Henry Schein (HSIC) on robust sales of PPE and COVID-19-related products.

Zacks Equity Research

PerkinElmer's (PKI) Horizon Discovery Broadens Portfolio

by Zacks Equity Research

PerkinElmer's (PKI) CRISPRi will help scientists get a firmer foothold in the biological pathways, processes and pathologies of disease.

Zacks Equity Research

Here's Why You Should Retain Merit Medical (MMSI) Stock Now

by Zacks Equity Research

Merit Medical (MMSI) continues to gain traction on a solid product portfolio and strong international exposure. However, stiff competition is worrisome.

Zacks Equity Research

OPKO Health (OPK) BioReference Extends COVID-19 School Testing

by Zacks Equity Research

OPKO Health's (OPK) BioReference expands COVID-19 testing in schools to create a safer learning environment for students, teachers, staff and their families.

Zacks Equity Research

Encompass Health (EHC) Opens Hospital, Boosts Texas Presence

by Zacks Equity Research

Encompass Health (EHC) opens an inpatient rehabilitation hospital in Texas, which reinforces the company's efforts to broaden presence in the state.